[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
All of the plasmid sequences were characterized by the presence of several selective antibiotic resistance genes from pUC19, pUB110, and pSM19035 vectors
ArticlePubMedPMCPDF 9
S.DunsmoreK
Semaglutide helps obese persons lose weight
The drug itself changes your relationship with food, Taylor said